The Food and Drug Administration (FDA) on Wednesday approved a new oral medication for weight loss, orforglipron, developed by Eli Lilly. Marketed under the brand name Foundayo, the pill represents the latest addition to a rapidly expanding array of powerful treatments for obesity.

Foundayo is the second daily pill for weight management to receive FDA clearance, following Novo Nordisk's Wegovy pill, which was approved in December 2025. Eli Lilly's clinical trials demonstrated that individuals with obesity achieved an average weight reduction of approximately 12 percent over 72 weeks when taking the highest dose of orforglipron. The medication functions by mimicking a naturally occurring hormone, thereby suppressing appetite and assisting in blood sugar regulation. Eli Lilly also intends to seek FDA approval for the drug's use in Type 2 diabetes later this year, having observed a 2.2 percentage point drop in average hemoglobin A1C values among Type 2 diabetes patients on the highest dose in a separate trial.

The approval intensifies competition between Eli Lilly and Novo Nordisk, which have been vying for market share with their injectable weight-loss treatments. Foundayo offers a potentially more convenient option for patients, as it can be taken at any time of day, with or without food. In contrast, the Wegovy pill requires consumption in the morning on an empty stomach. Dr. Melanie Jay, director of the NYU Langone Comprehensive Program on Obesity, noted that strict timing requirements can significantly reduce medication convenience for patients.

The new pill will be available in six dose levels, with uninsured patients paying between $149 and $349 per month. Medicare is anticipated to soon provide coverage for some eligible patients, with an expected co-pay of $50 per month, and private insurance plans are also expected to follow suit. Eli Lilly stated it would commence shipping Foundayo on Monday. The company has priced Foundayo to effectively match Novo Nordisk's Wegovy pill, which sells for $149 to $299 per month. Pricing agreements, established last fall with the Trump administration, also granted both Eli Lilly and Novo Nordisk vouchers for expedited FDA reviews, accelerating the market entry of both oral medications.

Patients taking orforglipron reported side effects similar to those associated with injectable weight-loss drugs, primarily gastrointestinal issues such as nausea and diarrhea. The medication may also reduce the effectiveness of oral birth control and is not advised for certain patients taking simvastatin, a common statin.

Dr. Kristina Henderson Lewis, a board member of the American Board of Obesity Medicine, highlighted that the growing number of treatment options empowers patients to collaborate more effectively with their healthcare providers. She emphasized that individuals can now have discussions with their doctors about selecting the most suitable medication based on factors like convenience, side-effect profiles, and cost.